Cryo Cell International vs Haoxi Health Technology
Haoxi Health Technology is the larger business, with $54.8m of revenue in fiscal 2026 against $31.6m for Cryo Cell International (1.7 times as much). Haoxi Health Technology grew faster (67.1% against -1.3%). Cryo Cell International kept more of each dollar of sales as profit: a net margin of -7.7% against -17.4%.
| Latest fiscal year | Cryo Cell InternationalCCEL, 2025 | Haoxi Health TechnologyHAO, 2026 |
|---|---|---|
| Revenue | $31.6m | $54.8m |
| Revenue growth | -1.3% | 67.1% |
| Net income | −$2.4m | −$9.5m |
| Operating margin | 1.5% | -17.6% |
| Net margin | -7.7% | -17.4% |
| Return on equity | — | -54.1% |
| Free cash flow | $5.2m | −$2.6m |
| Cash | $319,031 | $10.9m |
| Total debt | $10.7m | $290,710 |
| Debt to equity | — | 1.6% |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | $169,502 | — |
| Employees | 72 | — |
| Market value | $40.7m | $46,645 |
| Price vs our value range | Below our value range | — |
| Moat score | 73 (Strong) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 0 sales |